TB-500 Research for Corneal Healing
An evidence-based overview of research examining TB-500 in the context of corneal healing. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymosin beta-4's most advanced clinical application is in ophthalmology. A randomized, placebo-controlled Phase 3 trial demonstrated that 60% (6 of 10) of patients with neurotrophic keratopathy achieved complete corneal healing with RGN-259 (Tb4 eye drops) versus 12.5% (1 of 8) with placebo, a strong efficacy trend in this small study. The mechanism involves promotion of corneal epithelial cell migration and reduction of inflammation via NF-kB suppression. Dry eye trials also showed improvements in corneal staining and tear breakup time. Note: These trials used RGN-259 (purified thymosin beta-4), not TB-500. The published neurotrophic keratopathy Phase 3 (SEER-1, n=18) showed a strong healing trend but did not reach statistical significance on its primary endpoint (p=0.066), and a confirmatory Phase 3 (SEER-2) remains ongoing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. TB-500 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.